Angiotensin receptor blockers: Cardiovascular protection in the metabolic syndrome

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 7, Issue SUPPL. 1, 2006, Pages

  Deedwania, Prakash C ^a,c   Schmieder, Roland ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Cardiology Division   (United States)

Author keywords

Angiotensin receptor blockers; Hypertension; Metabolic syndrome; Valsartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NATEGLINIDE; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CALORIC RESTRICTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG TARGETING; DYSLIPIDEMIA; ELECTROCARDIOGRAM; EXERCISE; FAMILY HISTORY; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRACTICE GUIDELINE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SYMPTOMATOLOGY; WAIST CIRCUMFERENCE;

EID: 33748670464     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2006.018     Document Type: Article

References (57)

1. Deedwania PC. Metabolic syndrome and vascular disease. Is nature or nurture leading the new epidemic of cardiovascular disease? Circulation 2004;109:2-4.
2. Hall JE, Crook ED, Jones DW, Wofford MR, Dubbert PM. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002;324:127-37.
3. Deedwania PC, Volkova N. Current treatment options for the metabolic syndrome. Curr Treat Options Cardiovasc Med 2005;7:61-74.
4. Landsberg L. Insulin and hypertension: lessons from obesity. N Engl J Med 1987;317:378-95.
5. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993;44:121-31.
6. Grundy SM, Brewer HB, Cleeman JI et al. Definition of metabolic syndrome: report of the National Heart, Lung and Blood Institute/ American Heart Conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004;24:e13-18.
7. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III. JAMA 2001;285:2486-97.
9. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
10. Ninomiya JK, L'Italien G, Criqui MH et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004;109(1):42-6.
11. Laaksonen DE, Lakka HM, Niskanen LK et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002;156:1070-7.
12. Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the "metabolic syndrome" and incidence of Type 2 diabetes. Diabetes 2002;5:3120-7.
13. Grundy SM, Hansen B, Smith SC Jr et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004;109:551-6.
14. Després JP. Health consequences of visceral obesity. Ann Med 2001;33:534-41.
15. Montalescot G, Collet JP. Preserving cardiac function in the hypertensive patient: why renal parameters hold the key. Eur Heart J 2005;8:[ePub ahead of print]
16. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabet Care 2002;25:1177-84.
17. Sattar N, Gaw A, Scherbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-19.
18. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003; 108:1527-32.
19. McNeill AM, Rosomond WD, Girman CJ et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk In Communities study. Diabet Care 2005;28:385-90.
20. Lakka H, Laaksonen D, Lakka T et al. The metabolic syndrome and total and cardiovascular disease mortality in middle aged men. JAMA 2002;288:2709-16.
21. Zeller M, Steg PG, Ravisy J et al. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med 2005;165:1192-8.
22. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and Type 2 diabetes mellitus. Circulation 2005;112:3066-72.
23. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabet Care 1999;22:141-6.
24. Solomon CG, Hu FB, Dunaif A et al. Long or highly irregular menstrual cycles as a marker for risk of Type 2 diabetes mellitus. JAMA 2001;286:2421-6.
25. Hanley A, Wagenknecht L, Festa A et al. Liver markers and risk of incident metabolic syndrome (MetS) [abstract]. Program and abstracts of the 65th Scientific Sessions of the American Diabetes Association; June 10-14, 2005; San Diego, California.
26. Eckel RH, Krauss RM. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 1998;97:2099-100.
27. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
28. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991;121:1244-63.
29. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000;355:637-45.
30. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 1999;12:205S-213S.
31. Cohn JN, Tognoni G for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
32. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
33. Julius S, Kjeldsen SE, Weber M et al. for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
34. Corea L, Cardoni O, Fogari R et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996;60:341-6.
35. Hegner G, Faust G, Freytag F, Meilenbrock S, Sullivan J, Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide. Eur J Clin Pharmacol 1997;52:173-7.
36. Mallion J-M, Boutelant S, Chabaux P et al. Valsartan, a new angiotensin II antagonist: blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril. Blood Press Monit 1997;2:179-84.
37. Mahmud A, Feely J. Favourable effects on arterial wave reflection and pulse pressure amplification of adding angiotensin II receptor blockade in resistant hypertension. J Hum Hypertens 2000; 14:541-6.
38. Fogari R, Zoppi A, Carretta R, Veglio F, Salvetti A for the Italian Collaborative Study Group. Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study. J Hypertens 2002;20:1007-14.
39. Campbell R, Sangalli F, Perticucci E et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003; 63:1094-103.
40. Klingbeil AU, John S, Schneider MP, J Jacobi, Handrock R, Schmieder RE. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003; 16:123-8.
41. Mallion J-M, Carretta R, Trenkwalder P et al. Valsartan/ hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press 2003;12(Suppl 1):36-43.
42. Calvo C, Hermida RC, Ayala DE, Ruilope LM. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens 2004;22:837-46.
43. Waeber B, Aschwanden R, Sadecky L, Ferber P. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. J Hypertens 2001;19:2097-104.
44. Fogari R, Mugellini A, Zoppi A et al. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol 2004a;59:863-8.
45. Malacco E, Piazza S, Scandiani L, Zoppi A. Valsartan/hydrochlorothiazide versus amlodipine on ambulatory blood pressure and plasma norepinephrine levels in high-risk hypertensive patients. Adv Ther 2004;21:149-61.
46. Malacco E, Vari N, Capuano V et al. for the Val-Syst Investigators. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst Study. Clin Ther 2003;25:2765-80.
47. Ruilope LM, Malacco E, Khder Y, Kandra A, Bonner G, Heintz D. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther 2005;27:578-87.
48. Cifkova R, Peleška J, Hradec J et al. Valsartan and atenolol in patients with severe essential hypertension. J Hum Hypertens 1998;12:563-7.
49. Fogari R, Preti P, Zoppi A et al. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women. Am J Hypertens 200;17:77-81.
50. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
51. Whitworth JA. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983-92.
52. Kjeldsen SE, Julius S, Weber MA, Stolt P. Main results from VALUE. In: Oparil S, Weber MA, eds. Hypertension: A Companion to Brenner and Rector's The Kidney. 2nd ed. Philadelphia, PA: Elsevier Saunders; 2005:376-80.
53. Fogari R, Derosa G, Zoppi A et al. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res 2005;28:209-14.
54. Nomura S, Shouzu A, Omoto S et al. Effect of valsartan on monocyte/ endothelial cell activation markers and adiponectin in hypertensive patients with Type 2 diabetes mellitus. Thromb Res 2006;117:385-92.
55. McMurray JJ, Califf R, Holman R et al. Cardiologists should care about glucose: most people with cardiovascular disease or risk factors have diabetes or significant glycaemic abnormalities. Results of screening over 39,000 subjects for NAVIGATOR [abstract]. Eur Heart J 2004;25(Suppl):239.
56. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents Type 2 diabetes formation by fat cells. Hypertension 2002;40:609-11.
57. Cooper ME. The role of the renin-angiotensin aldosterone system in diabetes and its vascular complications. Am J Hypertens 2004;17:16S-20S.